Cancer Treatment Today

NovoSeven® RT (coagulation Factor VIIa) is used to manage severe bleeding in patients with hemophilia or inhibitors, not for routine dental cleaning. It has been used for Factor XI deficient pateints with inhibitors; in this case, there is no information on the presence or absence of inhbitos. Bleeding tendency does not always correlate with FXI plasma levels or genotype. However, Factor VII patients vary greatly in their propensity to bleed, and the best predictor of future risk is past history. It appears that there was bleeding after cleaning and whether it responded to tranxemic acid therapy alone is not provided

Availabel literature on teh use of Factor CII for factor XI deficiency is restricted to more morbis and risky procedures. Post-denatal cleaning bleeding is of a lower order of risk. It is noted that this claimant had a reaction to FFP a., limiting her options., A recent review article by Barg et al, does not recommendits use for minor procedures..

Novo-Seven is indiactec for treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
•
Assaf Arie Barg, Tami Livnat, Gili Kenet, Factor XI deficiency: phenotypic age-related considerations and clinical approach towards bleeding risk assessment. Blood (2024) 143 (15): 1455–1464.

Novo_seven Prescribing Information 2026

Factor XI deficiency and Its Management, Third Edition, April 2008, Published by the World Federation of Hemophilia (WFH),